Pfizer will acquire biotech Metsera for $4.9B in cash, expanding its obesity treatment portfolio with milestone payments possibly raising the deal to $7.3B.
Novo Nordisk’s amycretin shows up to 22% weight loss in trials, boosting its stock by 6.87% as the drug exhibits safety and potential as a next-gen obesity treatment.
